Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Koppert presents new biocontrol agents

Dutch bioproducts company Koppert Biological Systems (Berkel en Rodenrijs) has developed a new biological control product for thrips and whiteflies using the predatory mite, Amblydromalus limonicus.. It is the only predatory mite that eats larger thrips larvae (phases L1 and L2) and eggs, as well as all larval stages of whiteflies, Koppert says. A limonicus also surpasses other predatory mites in being active across a broad temperature range from 13°C to 30°C. Koppert says that A limonicus is known as an effective, but difficult-to-produce, natural enemy of thrips and whiteflies. It has resolved the production problem and plans deliveries for early 2012. The company has also produced a variant of its Amblyseius swirskii predatory mite-based product. Swirski-Mite LD (Long Duration) remains present in the crop for longer as it releases mites over a longer period. That makes it ideally suited to a preventative approach.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG005366

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel